The introduction of Ozempic and Wegovy has significantly impacted the fight against obesity in America. However, amidst the discussions about their cosmetic benefits and potential medical risks, it is essential to remember that obesity is a major risk factor for preventable deaths in the United States. Exciting next-generation alternatives may prove to be even more effective and show promising off-label implications. Some patients have reported a decrease in compulsive behavior related to various addictions when using these drugs.
In the field of gene therapy, Crispr has demonstrated significant progress since its first use in the United States four years ago for sickle-cell disease. It has expanded to include testing for congenital blindness, heart disease, diabetes, cancer, and HIV. Although only two applications have been submitted to the F.D.A., there are approximately 400 million people worldwide suffering from diseases caused by single-gene mutations. These diseases could potentially be treated with Crispr. Looking ahead, the future possibilities are incredibly promising, including genetic protection against high cholesterol, coronary artery disease, Alzheimer’s, and dementia.
‘Can we actually do it?’
A recent study published in Nature suggested that the rate of disruptive scientific breakthroughs has been declining due to specialized research fields and limited exploration beyond established science. However, in the field of vaccine and treatment development, we are witnessing the culmination of decades of research. While this does not imply exponential progress towards radical life extension or the complete eradication of cancer, the advancements are significant and should be accelerated further.
During the pandemic, there have been calls to expedite progress, including reducing the costs of drug development and improving the clinical trial and drug approval processes. There is also a focus on addressing global distribution and access to these new technologies. The necessary biology and science are already in place, but the question remains: Can we effectively implement them?
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
